{"groups":[{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n70 mg twice daily.\n\nDS-1594b: Given DS-1594b PO","id":"FG000","title":"Phase I (DS-1594b) Cohort 1"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n50 mg twice daily.\n\nDS-1594b: Given DS-1594b PO","id":"FG001","title":"Phase I (DS-1594b) Cohort 2"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n20 mg daily.\n\nDS-1594b: Given DS-1594b PO","id":"FG002","title":"Phase I (DS-1594b) Cohort 3"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n50 mg daily.\n\nDS-1594b: Given DS-1594b PO","id":"FG003","title":"Phase I (DS-1594b) Cohort 4"},{"description":"Patients receive DS-1594b PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.\n\n100 mg daily.\n\nDS-1594b: Given DS-1594b PO","id":"FG004","title":"Phase I (DS-1594b) Cohort 5"},{"description":"Patients with MLLr or NPM1m receive DS-1594b PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nDS-1594b: Given DS-1594b PO","id":"FG005","title":"Phase 2 Cohort A and B (DS-1594b)"},{"description":"Patients receive DS-1594b PO BID on days 1-28, venetoclax PO QD on days 1-28, and azacitidine IV or SC on days 1-7. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.\n\nDS-1594b: Given DS-1594b PO\n\nAzacitidine: Given IV or SC\n\nVenetoclax: Given PO","id":"FG006","title":"Phase 2 Cohort C (DS-1594b, Venetoclax, Azacitidine)"},{"description":"Patients receive DS-1594b PO BID on days 1-28. For additional information, see trial description.\n\nDS-1594b: Given DS-1594b PO\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IT\n\nDexamethasone: Given PO or IV\n\nFilgrastim: Given SC\n\nLeucovorin: Given IV or PO\n\nMesna: Given IV\n\nMethotrexate: Given IT\n\nPrednisone: Given PO\n\nRituximab: Given IV\n\nVincristine: Given IV","id":"FG007","title":"Phase 2 Cohort D (DS-1594b, Mini-HCVD)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Participant were only enrolled in the phase 1 portion of this study. The study was terminated early and did not move on to Phase 2."}